Table 3.

Univariate and multivariate analysis evaluating the relationship between intermediate-poor risk long-term responders and clinicopathological factors

	Univariate analysis			Multivariate analysis
	HR	95% CI	P value	HR	95% CI	P value
Age > 70	1.12	0.39–3.18	0.82
Gender, male	0.45	0.19–1.05	0.06
Histology clear-cell RCC	0.98	0.73–1.31	0.98
Previous nephrectomy, Yes	6.35	1.4–27.6	0 . 0 1	8.24	1.8–37.7	0 . 0 0 7
ECOG PS ≥ 1	0.40	0.16–0.94	0 . 0 3	0.34	0.13–0.88	0 . 0 2 7
Sarcomatoid feature, Yes	0.72	0.4–1.32	0.29
Metastatic sites, n (%)
Lung	0.7	0.31–1.59	0.40
Liver	0.66	0.21–2.04	0.48
Nodal	1.1	0.49–2.48	0.80
Bone	0.5	0.2–1.2	0.12
Brain	0.01	0.00–1.1	0.90
Line of therapy after TKI > 1, n (%)	0.21	0.08–0.53	0.11	0.13	0.05–0.35	0 . 0 0 1

ECOG PS: Eastern Cooperative Oncology Group Performance Status Scale; RCC: Renal cell carcinoma; TKI: Tyrosine kinase inhibitor.